代谢功能障碍相关脂肪性肝病认知度低且筛查机会被错过:英国人群与临床医生调查结果
该横断面研究通过两项在线调查评估英国公众和基层/专科医生对MASLD的认知与筛查实践。在2114名公众中,71%知晓「脂肪肝」,仅5%知晓MASLD;158名医生中57%知晓MASLD,仅44%报告筛查患者。研究提示需加强针对性教育和指南推广以促进早期诊断。
要点
- 公众对MASLD的知晓率仅5%,远低于脂肪肝(71%)和NAFLD(38%)。
- 仅44%的医生报告对任何患者进行MASLD筛查,主要障碍为不熟悉指南和筛查工具可及性差。
- MASLD高风险人群、60岁以下、高教育程度和女性更可能知晓该病。
核心结论
- 亟需提高公众和医生对MASLD的认知并促进指南采纳,以实现早期诊断和干预。
研究设计与样本
- 横断面研究,包含两项在线调查:苏格兰普通人群和英国基层及二级医疗医生。
- 人群调查样本量为2114人;医生调查样本量为158人。
主要发现
- 人群调查中71%知晓「脂肪肝」,5%知晓MASLD,38%知晓NAFLD(P < .001)。
- MASLD高风险、60岁以下、高教育程度和女性受访者更可能知晓该病(均P < .01)。
- 98%的人群受访者若患病希望获得MASLD诊断。
- 医生中脂肪肝知晓率100%,NAFLD 98%,MASLD 57%(P < .001)。
- 仅44%医生报告筛查任何患者,障碍包括不熟悉指南、筛查工具可及性有限和转诊路径不清。
临床怎么用
- 消化内科医生应主动对高风险人群进行MASLD筛查,并熟悉相关指南和推荐筛查工具。
- 需加强公众教育以提高MASLD疾病名称的认知,促进患者主动就医。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 30% of adults but remains under-recognized. Guidelines recommend screening in high-risk groups; however, MASLD awareness among patients and health care practitioners (HCPs) remains poor, with gaps in knowledge and implementation persisting. We undertook 2 national surveys to quantify MASLD awareness and knowledge gaps and explore screening practices among HCPs. METHODS: This cross-sectional study comprised 2 online surveys of the general population in Scotland and United Kingdom HCPs (primary and secondary care). Surveys assessed recognition of MASLD and associated conditions, factors influencing awareness (including inequalities), and HCP screening practices. RESULTS: In the population survey (n = 2114), 71% of respondents were aware of 'fatty liver disease,' compared with 5% for MASLD, and 38% for nonalcoholic fatty liver disease (P < .001). Respondents at higher risk of MASLD, aged less than 60 years, with higher educational attainment, and of female sex, were more likely to be "aware" (all P < .01). Most population respondents (98%) reacted positively to wanting a MASLD diagnosis if present. Among HCPs (n = 158), the awareness of fatty liver disease (100%) and nonalcoholic fatty liver disease (98%) was significantly higher than that of MASLD (57%; P < .001). Only 44% of HCPs reported screening any patients for MASLD. Barriers cited included a lack of familiarity with guidelines, limited access to recommended screening tools, and unclear specialist referral pathways. CONCLUSIONS: Improved awareness and guideline adoption are imperative to facilitate earlier MASLD diagnosis and intervention. Our findings suggest targeted education for awareness and equitable public health strategies are still needed to address knowledge and management gaps in the United Kingdom among both the general population and HCPs.
引用
- Leith D, Brennan PN, Lynch RW, et al. Low Metabolic Dysfunction-Associated Steatotic Liver Disease Awareness and Missed Screening Opportunities: Results From a United Kingdom Population and Clinician Survey. Clin Gastroenterol Hepatol. 2026. PMID: 42648517. doi:10.1016/j.cgh.2026.07.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。